Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dianthus Therapeutics (DNTH) Long-Term Investments (2024 - 2025)

Dianthus Therapeutics (DNTH) has 2 years of Long-Term Investments data on record, last reported at $152.9 million in Q3 2025.

  • For Q3 2025, Long-Term Investments rose 148.65% year-over-year to $152.9 million; the TTM value through Sep 2025 reached $152.9 million, up 148.65%, while the annual FY2024 figure was $81.7 million, N/A changed from the prior year.
  • Long-Term Investments reached $152.9 million in Q3 2025 per DNTH's latest filing, up from $51.7 million in the prior quarter.
  • Across five years, Long-Term Investments topped out at $152.9 million in Q3 2025 and bottomed at $51.7 million in Q2 2025.